おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Grail
company
About
Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
- 501 - 1000
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $300M
- Industries
- Biotechnology,Health Care,Health Diagnostics,Medical,Medical Device
- Founded date
- Jan 1, 2016
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$1.61B
Grail has raised a total of
$1.61B
in funding over 2 rounds. Their latest funding was raised on
May 21, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 21, 2018 | Series C | $300M | 1 | — | — | Detail |
| Mar 1, 2017 | Series B | $1.21B | 1 |
ARCH Venture Partners
|
— | Detail |
| Jan 12, 2016 | Series A | $100M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Grail is funded by 2 investors.
ARCH Venture Partners
and China Merchants Securities
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
Yes | Series B |
China Merchants Securities
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
